Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities (2021 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Gains from Investment Securities of -$228965.0 for Q1 2026, down 609.08% on a YoY basis from $44976.0 in Q1 2025, and down 390.71% sequentially from -$46660.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 6 years of Gains from Investment Securities data on file, last reported at -$228965.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 609.08% year-over-year to -$228965.0; the trailing twelve-month figure through Mar 2026 stood at -$227372.0 (up 80.82% YoY), and the FY2025 full-year result was $46569.0, up 103.19% from the prior year.
- Gains from Investment Securities eased to -$228965.0 in Q1 2026, from -$46660.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $370464.0 in Q1 2022 to a low of -$1.0 million in Q4 2022.
- A 5-year average of -$293255.1 and a median of -$230430.0 in 2024 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities soared 119.52% in 2025 and plunged 609.08% in 2026, its largest moves.
- Tracing CPIX's Gains from Investment Securities over 5 years: stood at -$1.0 million in 2022, then soared by 77.22% to -$236128.0 in 2023, then slumped by 122.22% to -$524732.0 in 2024, then jumped by 91.11% to -$46660.0 in 2025, then slumped by 390.71% to -$228965.0 in 2026.
- Business Quant data shows CPIX's Gains from Investment Securities at -$228965.0 in Q1 2026, -$46660.0 in Q4 2025, and $9651.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -228,965.00 |
| Mar 31, 2026 | -228,965.00 |
| Dec 31, 2025 | -46,660.00 |
| Dec 31, 2025 | -46,660.00 |
| Sep 30, 2025 | 9,651.00 |
| Sep 30, 2025 | 9,651.00 |
| Jun 30, 2025 | 38,602.00 |
| Jun 30, 2025 | 38,602.00 |
| Mar 31, 2025 | 44,976.00 |
| Mar 31, 2025 | 44,976.00 |
| Dec 31, 2024 | -524,732.00 |
| Dec 31, 2024 | -524,732.00 |
| Sep 30, 2024 | -493,751.00 |
| Sep 30, 2024 | -493,751.00 |
| Jun 30, 2024 | -211,891.00 |
| Jun 30, 2024 | -211,891.00 |
| Mar 31, 2024 | -230,430.00 |
| Mar 31, 2024 | -230,430.00 |
| Dec 31, 2023 | -236,128.00 |
| Dec 31, 2023 | -236,128.00 |